Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy

Proteomics - Clinical Applications

Volumn 7, Issue 5-6, 2013, Pages 316-326

  Morrissey, Brian ^a   O'Shea, Carmel ^b   Armstrong, John ^b   Rooney, Cathy ^a   Staunton, Lisa ^a   Sheehan, Martina ^b   Shannon, Aoife M ^c   Pennington, Stephen R ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST LUKE S HOSPITAL   (Ireland)

^c All Ireland Co operative Oncology Research Group   (Ireland)

Author keywords

Biomarker; Clinical trial; Disease recurrence; Prostate cancer; Radiation therapy

Indexed keywords

ALBUMIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; CLUSTERIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C9; FICOLIN; FICOLIN 3; HAPTOGLOBIN; HEMOPEXIN; INTER ALPHA TRYPSIN INHIBITOR; PLASMINOGEN; SERUM AMYLOID P; TRANSFERRIN; TUMOR MARKER; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; VITRONECTIN;

ARTICLE; BLOOD SAMPLING; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE MARKER; GLEASON SCORE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMBINED MODALITY THERAPY; HUMANS; MALE; NANOTECHNOLOGY; PRINCIPAL COMPONENT ANALYSIS; PROSTATIC NEOPLASMS; RECURRENCE; TANDEM MASS SPECTROMETRY; TIME FACTORS; TRYPSIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84879452082     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201300004     Document Type: Article

References (39)

1. Ferlay, J., Parkin, D. M., Steliarova-Foucher, E., Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46, 765-781.
2. Heidenreich, A., Bellmunt, J., Bolla, M., Joniau, S. et al., EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. J. Cancer 2011, 59, 61-71.
3. Roach, M., Waldman, F., Pollack, A., Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 2009, 115, 3112-3120.
4. Manola, J., Loffredo, M., Renshaw, A. A., Dellacroce, A. et al., 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized. J. Am. Med. Assoc. 2004, 292, 821-827.
5. Bolla, M., De Reijke, T. M., Van Tienhoven, G., Van den Bergh, A. C. M. et al., Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 2009, 360, 2516-2527.
6. Horwitz, E. M., Bae, K., Hanks, G. E., Porter, A. et al., Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 2008, 26, 2497-2504.
7. Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D. et al., Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011, 12, 451-459.
8. Jones, C. U., Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl. J. Med. 2011, 365, 107-118.
9. Roach, M., Hanks, G., Thames, H., Schellhammer, P. et al., Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Oncol. Biol. Phys. 2006, 65, 965-974.
10. Simmons, M. N., Berglund, R. K., Jones, J. S., A practical guide to prostate cancer diagnosis and management. Cleveland Clin. J. Med. 2011, 78, 321-331.
11. Denham, J. W., Steigler, A., Wilcox, C., Lamb, D. S. et al., Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? Cancer 2009, 115, 4477-4487.
12. Sardana, G., Jung, K., Stephan, C., Diamandis, E. P., Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J. Proteome Res. 2008, 7, 3329-3338.
13. Skvortsov, S., Schaefer, G., Stasyk, T., Fuchsberger, C. et al., Proteomics profiling of microdissected low-and high-grade prostate tumors identifies lamin A as a discriminatory biomarker. J. Proteome Res. 2011, 10, 259-268.
14. M'Koma, A. E., Blum, D. L., Norris, J. L., Koyama, T. et al., Detection of pre-neoplastic and neoplastic disease ny MALDI profiling of urine. Biochem. Biophys. Res. Commun. 2008, 353, 829-834.
15. Rehman, I., Evans, C. a., Glen, A., Cross, S. S. et al., iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer. PloS One 2012, 7, e30885.
16. Cheung, P. K., Woolcock, B., Adomat, H., Sutcliffe, M. et al., Advances in brief protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res. 2004, 64, 5929-5933.
17. Connell, K. O., Prencipe, M., Neill, A. O., Corcoran, C. et al., The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines. Proteomics 2012, 12, 2115-2126.
18. Collins, B. C., Miller, C. A., Sposny, A., Hewitt, P. et al., Development of a pharmaceutical hepatotoxicity biomarker panel using a discovery to targeted proteomics approach. Mol. Cell. Proteom. 2012, 11, 394-410.
19. Elliott, M. H., Smith, D. S., Parker, C. E., Borchers, C., Current trends in quantitative proteomics. J. Mass Spectrom. 2009, 44, 1637-1660.
20. Domanski, D., Percy, A. J., Yang, J., Chambers, A. G. et al., MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma solid phase extraction. Proteomics 2012, 12, 1222-1243.
21. Anderson, L., Hunter, C. L., Quantitative mass spectrometric MRM assays for major plasma proteins. Mol. Cell. Proteom. 2005, 5, 573-588.
22. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteom. 2002, 1, 845-867.
23. Ray, S., Reddy, P. J., Jain, R., Gollapalli, K. et al., Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead. Proteomics 2011, 11, 2139-2161.
24. Oon, S. F., Pennington, S. R., Fitzpatrick, J. M., Watson, R. W. G., Biomarker research in prostate cancer-towards utility, not futility. Nature Rev. Urol. 2011, 8, 131-138.
25. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analyt. Biochem. 1976, 72, 248-254.
26. Laemmli, U., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680-685.
27. Candiano, G., Bruschi, M., Musante, L., Santucci, L. et al., Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004, 25, 1327-1333.
28. Elias, J. E., Gygi, S. P., Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 2007, 4, 207-214.
29. Maclean, B., Tomazela, D. M., Shulman, N., Chambers, M. et al., Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics 2010, 26, 966-968.
30. Keller, A., Eng, J., Zhang, N., Li, X. et al., A uniform proteomics MS/MS analysis platform utilizing open XML file formats. Mol. Syst. Biol. 2005, 1, 2005.0017.
31. Keshishian, H., Addona, T., Burgess, M., Kuhn, E. et al., Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteom. 2007, 6, 2212-2229.
32. Lau, T. Y. K., Power, K. A., Dijon, S., Gardelle, I. D. et al., Prioritization of candidate protein biomarkers from an in vitro model system of breast tumor progression toward clinical verification research articles. J. Proteome Res. 2010, 9, 1450-1459.
33. Fan, Y., Murphy, T. B., Byrne, J. C., Brennan, L. et al., Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J. Proteome Res. 2011, 10, 1361-1373.
34. Jenkins, R. E., Kitteringham, N. R., Hunter, C. L., Webb, S. et al., Relative and absolute quantitative expression profiling of cytochromes P450 using isotope-coded affinity tags. Proteomics 2006, 6, 1934-1947.
35. Chen, Y.-T., Chen, H. -W., Domanski, D., Smith, D. S. et al., Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J. Proteom. 2012, 75, 3529-3545.
36. Lange, V., Picotti, P., Domon, B., Aebersold, R., Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol. 2008, 4, 222.
37. Quintana, L. F., Campistol, J. M., Alcolea, M. P., Banon-Maneus, E. et al., Application of label-free quantitative peptidomics for the identification of urinary biomarkers of kidney chronic allograft dysfunction. Mol. Cell. Proteom. 2009, 8, 1658-1673.
38. Poste, G., Bring on the biomarkers. Nature 2011, 469, 156-157.
39. Armstrong, J. G., Gillham, C. M., Dunne, M. T., Fitzpatrick, D. A. et al., A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81, 35-45.